Predict your next investment

Corporation
HEALTHCARE | Biotechnology
ferring.com

See what CB Insights has to offer

Investments

1

Partners & Customers

10

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. Ferring Pharmaceuticals specializes in the areas of reproductive medicine and women’s health, urology and gastroenterology.

Ferring Pharmaceuticals Headquarter Location

Chemin de la Vergognausaz 50

Saint-Prex, 1162,

Switzerland

+41 (0)58 301 00 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ferring Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Ferring Pharmaceuticals in 2 Expert Collections, including Medical Devices.

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

W

Women's Health & Wellness

1,447 items

Startups focused on providing products and services catering to women's health and wellbeing.

Ferring Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ferring Pharmaceuticals Rank

Research containing Ferring Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ferring Pharmaceuticals in 1 CB Insights research brief, most recently on Nov 27, 2019.

Latest Ferring Pharmaceuticals News

Gender, health and racial inequalities to be tackled in flagship Ferring grant programme

Jan 27, 2022

€2.9 million awarded to 17 projects in Reproductive Medicine and Maternal Health in nine countries Programme reinforces Ferring’s #ProjectFamily Commitment to support everyone’s right to build a family Many inequalities and disparities in reproductive medicine and maternal health currently go unaddressed, due to a lack of dedicated research and investment January 27, 2022 08:00 AM Eastern Standard Time SAINT-PREX, Switzerland--( BUSINESS WIRE )--Forensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals grant programme unveiled today. The wide-ranging programme is designed to tackle inequalities and disparities in reproductive medicine and maternal health, reinforcing Ferring’s ambitious #ProjectFamily Commitment , which supports everyone’s right to build families of every shape and size. Through collaboration with people across the globe, Ferring has outlined how it will develop programs, services, and treatments to address unmet needs in reproductive medicine and maternal health. Millions of people around the world are unable to access the care, treatment and support they need to build a family, and so, the grants aim to support projects that focus on delivering better outcomes and solutions at every stage of the reproductive journey, from conception to birth. “At Ferring, we believe in everyone’s right to a family. That is why we are determined to play our part in collaborating to tackle some of the unique challenges faced by people across the globe when building families,” said Per Falk, President of Ferring Pharmaceuticals. “The projects funded by the grant programme aim to address some of the greatest global gender, health and racial inequalities in reproductive medicine and we look forward to realising positive outcomes of these projects.” Today’s announcement totals funding of nearly €2.9 million to support 17 projects in nine countries, including Australia, Brazil, Canada, Denmark, Ethiopia, South Sudan, Uganda, the United Kingdom and the United States. It includes the 12 inaugural winners of the Racial Equality Grants in Reproductive Medicine and Maternal Health, a dedicated research programme to deepen understanding and drive solutions to tackle racial disparities in reproductive medicine and maternal health. The programme comprehensively addresses the scope of this issue by funding innovative research proposals in epidemiology as well as basic, clinical, translational, and social sciences. The programme builds on the success of # ProjectFamily: Safe Birth initiative, a decade-long public-private partnership, which earlier this year introduced a heat-stable formulation to prevent excessive bleeding after childbirth, known as postpartum haemorrhage (PPH). By seeking to prevent PPH, Ferring will support efforts to protect the lives of 20 million women and their families by 2030. How the grants programme aligns to the Ferring #ProjectFamily Commitment: #1 Learning from patients to improve their treatment and care Key fact: Cancer treatments can reduce the chances of having a family, so fertility preservation interventions need to happen before treatment starts.1 Decisions regarding the potential risk to fertility therefore need to be made with extreme time pressure when the person is also dealing with the new cancer diagnosis. A recent UK survey highlighted problems in accessing fertility preservation for young cancer patients.2 Research grant: University of Edinburgh Development Trust and University Court of the University of Edinburgh and its research project, ‘Supporting Fertility Preservation Treatment Decision-Making’. This project will develop fertility preservation patient decision making aids to support cancer patients across Europe. This study will build on an existing web-based decision aid created by the research team and will create new tailored resources for different patient groups in a range of languages. #2 Collaborating to reduce maternal and infant mortality Key fact: In rural Ethiopia, unreliable or non-existent power supplies mean that women delivering at night may give birth in the dark, preventing midwives being able to detect or manage complications. Training midwives and providing safer birthing conditions by supplying light and reliable power is critical to addressing this. Support grant: Ferring is supporting GreenLamp, an organisation dedicated to improving conditions for mothers and babies in rural Ethiopia and its ‘Ethiopian Maternal Health Community Programme’ through a 5-year holistic model, which will lead to high impact and sustainable improvements in a region of rural Ethiopia with extreme unmet needs. Key fact: Every year, 70,000 women die from PPH,3 with the majority of deaths occurring in low- and lower-middle income countries.4 The majority of PPH deaths could be avoided through preventative approaches, however, this is not always the reality for those living in humanitarian crisis settings, for example conflict regions, natural disasters and public health emergencies. Research grant: The United Nations Population Fund (UNFPA) is collaborating with Ferring Pharmaceuticals to contribute to the body of evidence regarding the safe introduction of additional resources such as heat-stable carbetocin for the prevention of PPH in low resource humanitarian contexts such as Uganda and South Sudan. Through this, both organisations aim to contribute to providing access to safe birth in the most vulnerable settings. #3 Closing gender and racial inequality gaps in reproductive medicine and maternal health Key fact: Around the world, including in high income countries, black women and women of colour are more likely to die from complications during pregnancy and childbirth than white women. Startling racial disparities also exist in fertility treatment. Studies in the US suggest that black women may be twice as likely as white women to have fertility problems but are far less likely to seek or receive treatment that could help them to build their families.5 Furthermore, in the UK, minority ethnic groups undergoing fertility treatment are less likely to have a baby, with black couples having the lowest chance of successful treatment.6 Research grant: The Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health, a dedicated research programme to deepen understanding and, ultimately, drive solutions to tackle racial disparities in reproductive medicine and maternal health, including maternal mortality, in-vitro fertilisation (IVF), pregnancy and postpartum outcomes. #4 Working together to win hearts and minds Key fact: The fertility rate - the average number of children a woman gives birth to - is falling. If the number falls below approximately 2.1, then the size of the population starts to decrease. In 1950, women were having an average of 4.7 children in their lifetime. Research showed the global fertility rate nearly halved to 2.4 in 2017 - and projections indicate it will fall below 1.7 by 2100.7 In line with this, the number of babies born globally as a result of IVF increased from under one million in 2007, to over two million in 2012.8 Research grant: International Federation of Fertility Societies (IFFS) and its research project, ‘Global decreasing fecundity trends: Society changes and implications, fertility awareness and access to infertility care’. Research grant: Globe institute at the University of Copenhagen and Copenhagen University Hospital – Rigshospitalet research project, ‘Understanding the reproduction paradigm of humankind in the Anthropocene (‘Ancient Reproduction’)’ which aims to map the evolutionary history of reproductive dysfunction by evaluating changes in environmental pollution and associated biological responses over time. ENDS About the Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health The Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health (RMMH) aims to fund projects to deepen understanding and, ultimately, drive solutions to tackle racial disparities in RMMH, including maternal mortality, in-vitro fertilisation (IVF), pregnancy and postpartum outcomes. The Ferring Innovation Grants Programme for Racial Equality in RMMH provides research grants of up to €20,000 and aims to fund multidisciplinary research projects across four main areas: basic and translational; clinical; epidemiology and prevention; and social science research. The winners for 2021 included Monash University (Australia), Universidade Federal de Minas Gerais (Brazil), McMaster University (Canada), University of Copenhagen (Denmark), Boston IVF Fertility Clinic (USA), Boston University (USA), Foundation for Research and Education Excellence (USA), Johns Hopkins University (USA), Rejuvenating Fertility Center (USA) and Yale School of Medicine (USA). About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries and markets its products in 110 countries. # # # 1 Anderson RA, et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod 2018;33: 1281-1290. 2 Newton HL, Picton HM, Friend AJ, et al. Inconsistencies in fertility preservation for young people with cancer in the UK Archives of Disease in Childhood Published Online First: 20 September 2021. doi:10.1136/archdischild-2021-321873 3 World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: https://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed January 2022. 4 Say L, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014; 2 (6):e323-33. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed January 2022. 5 STAT. For black women, the isolation of infertility is compounded by barriers to treatment Available at: https://www.statnews.com/2020/10/14/for-black-women-isolation-of-infertility-compounded-by-barriers-to-treatment/ Last accessed January 2022. 6 Human Fertilisation & Embryology Authority (HFEA). UK ethnicity statistics for IVF and DI fertility treatment. Available at: https://www.hfea.gov.uk/about-us/publications/research-and-data/ethnic-diversity-in-fertility-treatment-2018/ Last accessed January 2022. 7 BBC News. Fertility rate: ‘Jaw-dropping’ global crash in children being born Available at: https://www.bbc.co.uk/news/health-53409521 Last accessed January 2022. 8 American Society for Reproductive Medicine (ASRM). The number of babies born globally after treatment with the assisted reproductive technologies (ART). Available at: https://www.fertstert.org/article/S0015-0282(13)02586-7/fulltext#relatedArticles Last accessed January 2022. Contacts

Ferring Pharmaceuticals Investments

1 Investments

Ferring Pharmaceuticals has made 1 investments. Their latest investment was in FerGene as part of their Corporate Minority on November 11, 2019.

CBI Logo

Ferring Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/25/2019

Corporate Minority

FerGene

$170M

Yes

16

Date

11/25/2019

Round

Corporate Minority

Company

FerGene

Amount

$170M

New?

Yes

Co-Investors

Sources

16

Ferring Pharmaceuticals Acquisitions

3 Acquisitions

Ferring Pharmaceuticals acquired 3 companies. Their latest acquisition was Rebiotix on April 05, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/5/2018

Convertible Note

$99M

$38.52M

Acquired

3

10/10/2017

Subscribe to see more

$99M

Subscribe to see more

10

2/19/2015

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

4/5/2018

10/10/2017

2/19/2015

Investment Stage

Convertible Note

Series D

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$38.52M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

3

10

10

Ferring Pharmaceuticals Partners & Customers

10 Partners and customers

Ferring Pharmaceuticals has 10 strategic partners and customers. Ferring Pharmaceuticals recently partnered with Hybio Pharmaceutical on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/20/2021

Partner

Hybio Pharmaceutical

China

Ferring Pharmaceuticals’ Collaboration with Hybio Pharmaceutical Co.

Ferring Pharmaceuticals announced its strategic collaboration with Hybio Pharmaceutical where the Marketing Authorization of Cetrotide in Mainland China will be transferred to Ferring Pharmaceuticals ; and Hybio Pharmaceutical will act as the contract manufacturing organization of Ferring Pharmaceuticals .

1

5/19/2021

Partner

CytoReason

Israel

Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment

Israeli startup CytoReason today announced a partnership with Swiss multinational , Ferring Pharmaceuticals , to establish new treatments for inflammatory bowel disease .

6

2/24/2021

Partner

Rebiotix, and MyBiotics Pharma

United States, and Israel

Ferring & Rebiotix joins MyBiotics in biotherapeutics deal to address vaginal health

Ferring Pharmaceuticals , Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis .

1

6/4/2020

Partner

Igenomix

Spain

Subscribe to see more

Subscribe to see more

10

11/25/2019

Partner

Blackstone

United States

Subscribe to see more

Subscribe to see more

10

Date

9/20/2021

5/19/2021

2/24/2021

6/4/2020

11/25/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Hybio Pharmaceutical

CytoReason

Rebiotix, and MyBiotics Pharma

Igenomix

Blackstone

Country

China

Israel

United States, and Israel

Spain

United States

News Snippet

Ferring Pharmaceuticals’ Collaboration with Hybio Pharmaceutical Co.

Ferring Pharmaceuticals announced its strategic collaboration with Hybio Pharmaceutical where the Marketing Authorization of Cetrotide in Mainland China will be transferred to Ferring Pharmaceuticals ; and Hybio Pharmaceutical will act as the contract manufacturing organization of Ferring Pharmaceuticals .

Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment

Israeli startup CytoReason today announced a partnership with Swiss multinational , Ferring Pharmaceuticals , to establish new treatments for inflammatory bowel disease .

Ferring & Rebiotix joins MyBiotics in biotherapeutics deal to address vaginal health

Ferring Pharmaceuticals , Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

6

1

10

10

Ferring Pharmaceuticals Team

11 Team Members

Ferring Pharmaceuticals has 11 team members, including former Chief Executive Officer, Robert Haigh.

Name

Work History

Title

Status

Robert Haigh

Chief Executive Officer

Former

Paul Navarre

Chief Executive Officer

Former

Keith James

President

Former

Pierre Rivière

President, Senior Vice President

Former

Ravi Tayi MD MPH

Chief Medical Officer

Former

Name

Robert Haigh

Paul Navarre

Keith James

Pierre Rivière

Ravi Tayi MD MPH

Work History

Title

Chief Executive Officer

Chief Executive Officer

President

President, Senior Vice President

Chief Medical Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.